Estrogen treatment in multiple sclerosis

被引：76

作者：

Gold, Stefan M.

Voskuhl, Rhonda R. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Multiple Sclerosis Program, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90024 USA

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2009年 / 286卷 / 1-2期

关键词：

Multiple sclerosis; Disease modifying treatment; Estrogen; Neuroprotection; Immunomodulation; Experimental autoimmune encephalomyelitis; Safety; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PREGNANCY HORMONE ESTRIOL; EARLIEST CLINICAL STAGE; CENTRAL-NERVOUS-SYSTEM; CA1 PYRAMIDAL CELLS; SPINAL-CORD-INJURY; RECEPTOR-ALPHA; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; BRAIN ATROPHY;

D O I：

10.1016/j.jns.2009.05.028

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Currently available treatments for multiple sclerosis (MS) reduce inflammatory lesions on MRI and decrease clinical relapses but have limited effects on disability. Novel treatment options that target both the inflammatory as well as the neurodegenerative component of the disease are therefore needed. A growing body of evidence from basic science and clinical studies Supports the therapeutic potential of estrogens in MS. Mechanisms of action include both immunomodulatory and directly neuroprotective pathways. A first pilot trial of oral estriol treatment showed encouraging results. There are now several phase II trials underway to further determine the efficacy of estrogen treatment in MS. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：99 / 103

页数：5

共 87 条

[1] PREGNANCY AND MULTIPLE-SCLEROSIS
ABRAMSKY, O
[J]. ANNALS OF NEUROLOGY, 1994, 36 : S38 - S41
[2] Regional brain atrophy is associated with physical disability in multiple sclerosis: Semiquantitative magnetic resonance imaging and relationship to clinical findings
Bakshi, R
Benedict, RHB
Bermel, RA
Jacobs, L
[J]. JOURNAL OF NEUROIMAGING, 2001, 11 (02) : 129 - 136
[3] Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists
Barkhem, T
Carlsson, B
Nilsson, Y
Enmark, E
Gustafsson, JÅ
Nilsson, S
[J]. MOLECULAR PHARMACOLOGY, 1998, 54 (01) : 105 - 112
[4] Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains
Bebo, BF
Fyfe-Johnson, A
Adlard, K
Beam, AG
Vandenbark, AA
Offner, H
[J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (03) : 2080 - 2089
[5] Neuroprotection against oxidative stress by estrogens: Structure-activity relationship
Behl, C
Skutella, T
Lezoualch, F
Post, A
Widmann, M
Newton, CJ
Holsboer, F
[J]. MOLECULAR PHARMACOLOGY, 1997, 51 (04) : 535 - 541
[6] 17-BETA ESTRADIOL PROTECTS NEURONS FROM OXIDATIVE STRESS-INDUCED CELL-DEATH IN-VITRO
BEHL, C
WIDMANN, M
TRAPP, T
HOLSBOER, F
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 216 (02) : 473 - 482
[7] THE CLINICAL COURSE OF MULTIPLE-SCLEROSIS DURING PREGNANCY AND THE PUERPERIUM
BIRK, K
FORD, C
SMELTZER, S
RYAN, D
MILLER, R
RUDICK, RA
[J]. ARCHIVES OF NEUROLOGY, 1990, 47 (07) : 738 - 742
[8] Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration
Bo, L
Vedeler, CA
Nyland, H
Trapp, BD
Mork, SJ
[J]. MULTIPLE SCLEROSIS, 2003, 9 (04): : 323 - 331
[9] Detection of ventricular enlargement in patients at the earliest clinical stage of MS
Brex, PA
Jenkins, R
Fox, NC
Crum, WR
O'Riordan, JI
Plant, GT
Miller, DH
[J]. NEUROLOGY, 2000, 54 (08) : 1689 - 1691
[10] CANTARELLA G, 2004, CELL DEATH DIFFE JAN

← 1 2 3 4 5 6 7 8 9 →